Evaluation of a multi-kinase inhibitor KRC-108 as an anti-tumor agent in vitro and in vivo

<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi et al. · Science · 2007 · 4.5K citations · Full text

Medicine, Oncology, Pharmacology +17

<i>EGFR</i> Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Susumu Kobayashi, Titus J. Boggon, Tajhal Dayaram et al. · New England Journal of Medicine · 2005 · 3.9K citations · Full text

Medicine, Oncology, Pharmacology +15

An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms

Helen Y. Zou, Qiuhua Li, Joseph H. Lee et al. · Cancer Research · 2007 · 750 citations · Full text

Medicine, Medicinal Chemistry, Oncology +16

Novel mutations of the MET proto-oncogene in papillary renal carcinomas

Laura S. Schmidt, Kerstin Junker, Noboru Nakaigawa et al. · Oncogene · 1999 · 505 citations

Medicine, Molecular Genetics, Oncology +13

TrkA overexpression enhances growth and metastasis of breast cancer cells

Chann Lagadec, Samuel Meignan, Éric Adriaenssens et al. · Oncogene · 2009 · 250 citations

Medicine, Cancer Biology, Oncology +14